Home » Topics » Regulatory » Patents

Patents
RSS

Pfizer describes substance P antagonists

April 17, 1997

Excitatory amino acid antagonists from Novartis

April 17, 1997

Retroviral protease inhibitors disclosed by DuPont Merck

April 17, 1997

Pharmacia & Upjohn describes agents for 5-HT1A receptor-mediated disorders

April 17, 1997

SKB describes 5-HT2C/5-HT2B antagonists

April 17, 1997

Novel bisphosphonates revealed by Yissum

April 17, 1997

Esters of estrogenic compounds from Lilly

April 16, 1997

Meiji Seika discloses new cardiotonic agents

April 16, 1997

5-HT2 antagonists/5-HT reuptake inhibitors described by Yamanouchi

April 16, 1997

Pola discloses antitumor/immunosuppressive agents

April 16, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...